Esperion to Acquire Corstasis Therapeutics for $75M Upfront, Expanding Cardiovascular Franchise with FDA-Approved Enbumyst
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion Therapeutics is acquiring Corstasis Therapeutics for $75 million upfront plus up to $180 million in milestones, adding the FDA-approved Enbumyst nasal spray to its cardiovascular franchise.
Key Events · M&A and Partnerships · ESPR
-
Acquisition Agreement
Esperion entered a definitive agreement to acquire Corstasis Therapeutics for $75 million in upfront cash.
-
Contingent Payments
Corstasis shareholders are eligible for up to an additional $180 million in regulatory and commercial milestones, plus low double-digit royalties on Enbumyst sales and follow-on products.
-
New Product Integration
The acquisition brings Enbumyst™ (bumetanide nasal spray), an FDA-approved diuretic for edema associated with congestive heart failure, hepatic, and renal disease, into Esperion's portfolio.
-
Strategic Expansion
This move is expected to leverage Esperion's existing cardiovascular commercial infrastructure, accelerate revenue growth, and address a multi-billion dollar U.S. market opportunity, aligning with its Vision 2040.
Analysis · ESPR · Life Sciences
Esperion Therapeutics is acquiring Corstasis Therapeutics, gaining global rights to Enbumyst, an FDA-approved nasal spray diuretic for edema associated with congestive heart failure, hepatic, and renal disease. This strategic acquisition, valued at $75 million upfront cash plus up to $180 million in potential regulatory and commercial milestones and low double-digit royalties, significantly expands Esperion's cardiovascular portfolio. The company plans to leverage its existing commercial infrastructure to drive double-digit revenue growth and address a multi-billion dollar market opportunity, aligning with its Vision 2040. The deal is expected to close in Q2 2026.
At the time of this filing, ESPR was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $781.7M. The 52-week trading range was $0.69 to $4.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.